Abeona Therapeutics Inc
PCJ
Company Profile
Business description
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Contact
6555 Carnegie Avenue
4th Floor
ClevelandOH44103
USAT: +1 646 813-4701
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
136
Stocks News & Analysis
stocks
Chart of the Week: Aussie dividend yields are less attractive than alternatives
The latest insights from our equity research team.
stocks
2 ASX shares that benefit from sticky inflation
Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,874.20 | 25.80 | 0.29% |
| CAC 40 | 8,091.30 | 14.86 | -0.18% |
| DAX 40 | 23,983.83 | 93.04 | -0.39% |
| Dow JONES (US) | 48,061.58 | 52.68 | -0.11% |
| FTSE 100 | 9,788.41 | 103.62 | 1.07% |
| HKSE | 25,468.78 | 233.37 | 0.92% |
| NASDAQ | 22,902.15 | 209.31 | -0.91% |
| Nikkei 225 | 49,512.28 | 128.99 | 0.26% |
| NZX 50 Index | 13,295.91 | 129.04 | -0.96% |
| S&P 500 | 6,761.35 | 38.91 | -0.57% |
| S&P/ASX 200 | 8,585.20 | 21.60 | 0.25% |
| SSE Composite Index | 3,870.28 | 45.47 | 1.19% |